| Blood transfusion management and transfusion-related outcomes in daratumumab-treated patients with relapsed or refractory multiple myeloma A Chari, S Arinsburg, S Jagannath, T Satta, I Treadwell, D Catamero, ... Clinical Lymphoma Myeloma and Leukemia 18 (1), 44-51, 2018 | 38 | 2018 |
| Outcomes and management of red blood cell transfusions in multiple myeloma patients treated with daratumumab A Chari, T Satta, A Tayal, S Jagannath, HJ Cho, S Parekh, K Lau, ... Blood 126 (23), 3571, 2015 | 16 | 2015 |
| Clinical experience of CAR T cells for multiple myeloma GL Simmons, T Satta, OC Puglianini Best Practice & Research Clinical Haematology 34 (3), 101306, 2021 | 9 | 2021 |
| Enhancing venetoclax activity in hematological malignancies T Satta, S Grant Expert opinion on investigational drugs 29 (7), 697-708, 2020 | 9 | 2020 |
| Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia–a propensity score analysis K Sasaki, H Kantarjian, E Jabbour, F Ravandi, K Takahashi, M Konopleva, ... haematologica 101 (8), e324, 2016 | 6 | 2016 |
| Dual mTORC1/2 inhibition synergistically enhances AML cell death in combination with the BCL2 antagonist venetoclax T Satta, L Li, SL Chalasani, X Hu, J Nkwocha, K Sharma, M Kmieciak, ... Clinical Cancer Research 29 (7), 1332-1343, 2023 | 3 | 2023 |
| Mechanisms underlying synergism between circularized tumor necrosis factor‐related apoptosis inducing ligand and bortezomib in bortezomib‐sensitive or‐resistant myeloma cells Y Leng, X Hu, L Li, J Nkwocha, T Satta, K Sharma, M Kmeiciak, H Zhou, ... Hematological Oncology 40 (5), 999-1008, 2022 | 3 | 2022 |
| Bayesian Network Meta-Analysis (NMA): Safety of Bortezomib, Thalidomide or Lenalidomide Containing Regimens for Transplant Ineligible Multiple Myeloma (MM) Patients T Satta, N Yamaguchi, A Malone, J Talcott, A Chari Blood 126 (23), 3030, 2015 | 2 | 2015 |
| High-grade neuroendocrine carcinoma of the bladder (large cell and small cell mixed): a literature review and case report of a rare bladder tumor T Satta, K Sasaki, Y Tsuura, K Shioi International Cancer Conference Journal 4, 249-253, 2015 | 2 | 2015 |
| Use of a Tissue-Targeting Recombinant Human Interleukin-22 Fusion Molecule (F-652) for the Treatment of Advanced Refractory Lower GI Acute Gvhd T Satta, EB Papadopoulos, B Gyurkocza, P Susman, A Singh, M Calafiore, ... Transplantation and Cellular Therapy, Official Publication of the American …, 2024 | | 2024 |
| Use of a Tissue-Targeting Recombinant Human Interleukin-22 Fusion Molecule (F-652) for the Treatment of Advanced Refractory Lower GI Acute Gvhd T Satta, EB Papadopoulos, B Gyurkocza, P Susman, A Singh, M Calafiore, ... Blood 142, 7019, 2023 | | 2023 |
| Frontline therapy with high-dose imatinib vs. 2nd generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia–A propensity score analysis K Sasaki, H Kantarjian, E Jabbour, F Ravandi, K Takahashi, M Konopleva, ... | | 2016 |
| Bayesian network meta-analysis (NMA) comparison of second-line cytotoxic chemotherapies in advanced or metastatic gastric cancer. N Yamaguchi, T Fujii, T Satta, JA Ajani, P Kozuch Journal of Clinical Oncology 33 (15_suppl), e15055-e15055, 2015 | | 2015 |
